• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

益气补肾调脂方抗非酒精性脂肪性肝炎的靶向微小RNA及潜在机制

The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against-Non-Alcoholic Steatohepatitis.

作者信息

Hong Wei, Li Songsong, Cai Yueqin, Zhang Tingting, Yang Qingrou, He Beihui, Yu Jianshun, Chen Zhiyun

机构信息

The Second Central Laboratory, The First Affliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.

Key Laboratory of Integrative Chinese and Western Medicine for the Diagnosis and Treatment of Circulatory Diseases of Zhejiang Province, Hangzhou, China.

出版信息

Front Pharmacol. 2020 Nov 12;11:529553. doi: 10.3389/fphar.2020.529553. eCollection 2020.

DOI:10.3389/fphar.2020.529553
PMID:33281601
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7688626/
Abstract

MicroRNAs (miRNAs) have emerged as potential therapeutic targets for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH). Traditional Chineses Medicine (TCM) plays an important role in the prevention or treatment of NAFLD/NASH. However, miRNA targets of TCM against NASH still remain largely unknown. Here, we showed that Yiqi-Bushen-Tiaozhi (YBT) recipe effectively attenuated diet-induced NASH in C57BL/6 mice. To identify the miRNA targets of YBT and understand the potential underlying mechanisms, we performed network pharmacology using miRNA and mRNA deep sequencing data combined with Ingenuity Pathway Analysis (IPA). Mmu-let-7a-5p, mmu-let-7b-5p, mmu-let-7g-3p and mmu-miR-106b-3p were screened as the main targets of YBT. Our results suggested that YBT might alleviate NASH by regulating the expression of these miRNAs that potentially modulate inflammation/immunity and oxidative stress. This study provides useful information for guiding future studies on the mechanism of YBT against NASH by regulating miRNAs.

摘要

微小RNA（miRNA）已成为非酒精性脂肪性肝病/非酒精性脂肪性肝炎（NAFLD/NASH）的潜在治疗靶点。传统中药（TCM）在NAFLD/NASH的预防或治疗中发挥着重要作用。然而，中药针对NASH的miRNA靶点仍 largely未知。在此，我们表明益气补肾调脂（YBT）方剂可有效减轻C57BL/6小鼠饮食诱导的NASH。为了鉴定YBT的miRNA靶点并了解潜在的作用机制，我们结合miRNA和mRNA深度测序数据并运用 Ingenuity Pathway Analysis（IPA）进行了网络药理学研究。Mmu-let-7a-5p、mmu-let-7b-5p、mmu-let-7g-3p和mmu-miR-106b-3p被筛选为YBT的主要靶点。我们的结果表明，YBT可能通过调节这些可能调节炎症/免疫和氧化应激的miRNA的表达来减轻NASH。本研究为指导未来关于YBT通过调节miRNA治疗NASH机制的研究提供了有用信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/52c394c61de5/fphar-11-529553-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/fcf1685ad2d1/fphar-11-529553-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/58b69d9a5abd/fphar-11-529553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/8c24174ed8b5/fphar-11-529553-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/710b5f0415e1/fphar-11-529553-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/33d7a002cc08/fphar-11-529553-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/437b641c9222/fphar-11-529553-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/e257597b7d5e/fphar-11-529553-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/9d3942376f3f/fphar-11-529553-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/52c394c61de5/fphar-11-529553-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/fcf1685ad2d1/fphar-11-529553-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/58b69d9a5abd/fphar-11-529553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/8c24174ed8b5/fphar-11-529553-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/710b5f0415e1/fphar-11-529553-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/33d7a002cc08/fphar-11-529553-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/437b641c9222/fphar-11-529553-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/e257597b7d5e/fphar-11-529553-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/9d3942376f3f/fphar-11-529553-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffaf/7688626/52c394c61de5/fphar-11-529553-g009.jpg

相似文献

1
The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against-Non-Alcoholic Steatohepatitis.益气补肾调脂方抗非酒精性脂肪性肝炎的靶向微小RNA及潜在机制
Front Pharmacol. 2020 Nov 12;11:529553. doi: 10.3389/fphar.2020.529553. eCollection 2020.
2
Yiqi-Bushen-Tiaozhi Recipe Attenuated High-Fat and High-Fructose Diet Induced Nonalcoholic Steatohepatitis in Mice Gut Microbiota.益气补肾调脂方对高脂高果糖饮食诱导的非酒精性脂肪性肝炎小鼠肠道菌群的影响。
Front Cell Infect Microbiol. 2022 Apr 22;12:824597. doi: 10.3389/fcimb.2022.824597. eCollection 2022.
3
Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review.miRNA 在非酒精性脂肪性肝病 (NAFLD) 和非酒精性脂肪性肝炎 (NASH) 中的作用：全面综述。
J Int Med Res. 2023 Sep;51(9):3000605231197058. doi: 10.1177/03000605231197058.
4
Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者内脏脂肪组织中 miRNAs 的差异表达。
Aliment Pharmacol Ther. 2010 Aug;32(3):487-97. doi: 10.1111/j.1365-2036.2010.04366.x. Epub 2010 May 22.
5
Deep sequencing profiles MicroRNAs related to Aspergillus fumigatus infection in lung tissues of mice.深度测序分析了与烟曲霉感染相关的 MicroRNAs 在小鼠肺部组织中的表达谱。
J Microbiol Immunol Infect. 2019 Feb;52(1):90-99. doi: 10.1016/j.jmii.2016.09.002. Epub 2017 Jun 22.
6
A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.14号染色体q32.2母系印记区域中的一系列微小RNA与小鼠模型中非酒精性脂肪性肝病进展相关
PLoS One. 2016 May 2;11(5):e0154676. doi: 10.1371/journal.pone.0154676. eCollection 2016.
7
Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis.脂肪变性和脂肪性肝炎患者血清中微小RNA谱分析
Front Cell Dev Biol. 2021 Sep 9;9:736677. doi: 10.3389/fcell.2021.736677. eCollection 2021.
8
MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis.非酒精性脂肪性肝炎相关肝癌发生过程中的微小RNA失调
Oncotarget. 2017 Aug 1;8(51):88517-88528. doi: 10.18632/oncotarget.19774. eCollection 2017 Oct 24.
9
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.miR-873-5p 靶向线粒体 GNMT-Complex II 界面，有助于非酒精性脂肪性肝病。
Mol Metab. 2019 Nov;29:40-54. doi: 10.1016/j.molmet.2019.08.008. Epub 2019 Aug 16.
10
Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease.在晚期非酒精性脂肪性肝病中，microRNA 加工酶的基因表达发生改变。
J Gastroenterol Hepatol. 2013 Aug;28(8):1410-5. doi: 10.1111/jgh.12268.

引用本文的文献

1
Transcriptome sequencing and bioinformatics analysis of gastrocnemius muscle in type 2 diabetes mellitus rats.2 型糖尿病大鼠比目鱼肌转录组测序及生物信息学分析。
BMC Musculoskelet Disord. 2024 Jun 8;25(1):457. doi: 10.1186/s12891-024-07568-x.
2
Transcriptomics reveals dynamic changes in the "gene profiles" of rat supraspinatus tendon at three different time points after diabetes induction.转录组学揭示了诱导糖尿病后三个不同时间点大鼠冈上肌腱“基因谱”的动态变化。
BMC Med Genomics. 2024 May 6;17(1):122. doi: 10.1186/s12920-024-01899-3.
3
Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review.

本文引用的文献

1
Anti-Inflammatory and Antioxidative Properties of Isoflavones Provide Renal Protective Effects Distinct from Those of Dietary Soy Proteins against Diabetic Nephropathy.异黄酮的抗炎和抗氧化特性提供了肾脏保护作用，与饮食大豆蛋白对糖尿病肾病的作用不同。
Mol Nutr Food Res. 2020 May;64(10):e2000015. doi: 10.1002/mnfr.202000015. Epub 2020 Apr 27.
2
Serum response factor (SRF) promotes ROS generation and hepatic stellate cell activation by epigenetically stimulating NCF1/2 transcription.血清反应因子 (SRF) 通过表观遗传刺激 NCF1/2 转录促进 ROS 生成和肝星状细胞活化。
Redox Biol. 2019 Sep;26:101302. doi: 10.1016/j.redox.2019.101302. Epub 2019 Aug 15.
3
基于网络药理学的中医治疗非酒精性脂肪性肝病研究进展
Front Pharmacol. 2024 Apr 17;15:1381712. doi: 10.3389/fphar.2024.1381712. eCollection 2024.
4
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies.中西医结合防治非酒精性脂肪性肝病：未来方向与策略
Chin Med. 2024 Feb 3;19(1):21. doi: 10.1186/s13020-024-00894-1.
5
Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review.miRNA 在非酒精性脂肪性肝病 (NAFLD) 和非酒精性脂肪性肝炎 (NASH) 中的作用：全面综述。
J Int Med Res. 2023 Sep;51(9):3000605231197058. doi: 10.1177/03000605231197058.
6
The IDI1/SREBP2 axis drives intrahepatic cholestasis and is a treatment target of San-Huang-Cai-Zhu formula identified by sequencing and experiments.IDI1/SREBP2轴驱动肝内胆汁淤积，是通过测序和实验确定的三黄柴胡方的治疗靶点。
Front Pharmacol. 2023 Feb 8;14:1093934. doi: 10.3389/fphar.2023.1093934. eCollection 2023.
7
Screening of potential key ferroptosis-related genes in sepsis.脓毒症中潜在关键铁死亡相关基因的筛选。
PeerJ. 2022 Sep 13;10:e13983. doi: 10.7717/peerj.13983. eCollection 2022.
8
Yinzhihuang oral liquid protects against non-alcoholic steatohepatitis via modulation of the gut-liver axis in mice.茵栀黄口服液通过调节小鼠肠-肝轴对非酒精性脂肪性肝炎具有保护作用。
Ann Transl Med. 2022 Jun;10(11):631. doi: 10.21037/atm-21-4809.
9
M2 macrophage-derived exosomal microRNA-411-5p impedes the activation of hepatic stellate cells by targeting CAMSAP1 in NASH model.在非酒精性脂肪性肝炎模型中，M2巨噬细胞衍生的外泌体微小RNA-411-5p通过靶向CAMSAP1抑制肝星状细胞的激活。
iScience. 2022 Jun 14;25(7):104597. doi: 10.1016/j.isci.2022.104597. eCollection 2022 Jul 15.
Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis.
非酒精性脂肪性肝炎小鼠模型中胆汁酸组成和分布的改变。
Toxicol Appl Pharmacol. 2019 Sep 15;379:114664. doi: 10.1016/j.taap.2019.114664. Epub 2019 Jul 12.
4
miRNAs and NAFLD: from pathophysiology to therapy.miRNAs 与非酒精性脂肪性肝病：从病理生理学到治疗。
Gut. 2019 Nov;68(11):2065-2079. doi: 10.1136/gutjnl-2018-318146. Epub 2019 Jul 12.
5
Prediction of VEGF-C as a Key Target of Pure Total Flavonoids From Citrus Against NAFLD in Mice via Network Pharmacology.基于网络药理学预测柑橘纯总黄酮抗小鼠非酒精性脂肪性肝病的关键靶点血管内皮生长因子C
Front Pharmacol. 2019 Jun 4;10:582. doi: 10.3389/fphar.2019.00582. eCollection 2019.
6
Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.微小RNA在非酒精性脂肪性肝病和非酒精性脂肪性肝炎病理生理学中的作用
Middle East J Dig Dis. 2018 Oct;10(4):213-219. doi: 10.15171/mejdd.2018.113. Epub 2018 Jul 17.
7
Past, present and future perspectives in nonalcoholic fatty liver disease.非酒精性脂肪性肝病的过去、现在和未来展望。
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):377-386. doi: 10.1038/s41575-019-0144-8.
8
let-7a suppresses liver fibrosis via TGFβ/SMAD signaling transduction pathway.let-7a通过TGFβ/SMAD信号转导通路抑制肝纤维化。
Exp Ther Med. 2019 May;17(5):3935-3942. doi: 10.3892/etm.2019.7457. Epub 2019 Apr 1.
9
Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model.发酵人参GBCK25可改善非酒精性脂肪性肝炎模型中的脂肪变性和炎症。
J Ginseng Res. 2019 Apr;43(2):196-208. doi: 10.1016/j.jgr.2017.10.002. Epub 2017 Oct 21.
10
Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.肝细胞癌中连接去分化与β-连环蛋白功能障碍的基因网络的动态变化和预测药物反应。
J Hepatol. 2019 Aug;71(2):323-332. doi: 10.1016/j.jhep.2019.03.024. Epub 2019 Apr 4.